Anlotinib was developed as an oral molecular TKI that targets vascular endothelial growth factor 1 (VEGFR1), VEGFR2, VEGFR3, platelet-derived growth factor receptors (PDGFR) α, c-Kit, and fibroblast growth factor receptors (FGFRs) 1–3 and inhibits tumor angiogenesis and tumor cell proliferation (9, 12). This evidence concerns the gene PDGFRB and neoplasm.